Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Completed × Spironolactone × Clear all

Phase

Phase NA 2 Phase 2 2 Phase EARLY_PHASE1 1

Status

Recruiting 2 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 1 Inflammation 1

Interventions

Magnetic Resonance Spectroscopy 21 Metformin 13 pembrolizumab 10 Biopsy 10 Radiotherapy 7 Cyclophosphamide 7 Sirolimus 6 Nivolumab 6 Bevacizumab 6 gallium 68 PSMA-11 5 Rituximab 5 Granulocyte Colony-Stimulating Factor 5 Fluorouracil 5 Etoposide 5 Radiosurgery 4 Radiation 4 Methotrexate 4 Fluorodeoxyglucose F18 4 Filgrastim 4 Doxorubicin 4 Cisplatin 4 Aspirin 4 poly ICLC 3 olaparib 3 fluciclovine F-18 3 durvalumab 3 Vitamin D 3 Vincristine 3 Valproic Acid 3 Temozolomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02689843 2019-11-12

AntiPCO

Shiraz University of Medical Sciences

Phase EARLY_PHASE1 Completed

Inflammation, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡